Opthea Limited
ASX OPT.AX
Opthea Limited Net Cash Used Provided By Financing Activities for the year ending June 30, 2024: USD 243.73 M
-
Opthea Limited Net Cash Used Provided By Financing Activities for the year ending June 30, 2023 was USD 248.70 M, a 105,002.38% change year over year.
-
Opthea Limited Net Cash Used Provided By Financing Activities for the year ending June 30, 2022 was USD 236.62 K, a -99.85% change year over year.
-
Opthea Limited Net Cash Used Provided By Financing Activities for the year ending June 30, 2021 was USD 156.76 M.
| Date | Net Cash Used Provided By Financing Activities | Dividends Paid | Capital Expenditure | Effect Of Forex Changes On Cash |
|---|
Don’t Miss A Beat
| CEO | Dr. Frederic Guerard M.S., Pharm.D. |
| IPO Date | Jan. 31, 1988 |
| Location | Australia |
| Headquarters | 650 Chapel Street |
| Employees | 33 |
| Sector | Consumer Discretionary |
| Industries | |
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema (DME), as well as a first in class VEGF-C/D inhibitors for treatment with VEGF-A inhibitors to treat wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
Past 5 years
USD 1.23
StockViz Staff
February 7, 2025
Any question? Send us an email